Key facts
- It has raised $15.7M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Changxing Fund, The Chinese Academy of Sciences Venture Capital Management, Beijing Wenzhi Private Equity Fund Management, Future Capital (China), Institute of Advanced Technology — 10 tracked in total.
- Status: Privately Held (backing).
Investors
10- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Tongling Bionic
- ·The full record, as it builds
Funding rounds
No funding rounds for Tongling Bionic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tongling Bionic
Provider of heart failure diagnosis, treatment and rehabilitation designed for heart failure patients. The company focuses on researching and developing series of medical plan and assisting equipment, enabling patients to be treated and recovered efficiently.
- Sector
- Healthcare
- HQ
- Hefei, China
- Founded
- 2016
- Website
- telelife.com.cn/
- Ownership
- Privately Held (backing)
Tongling Bionic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tongling Bionic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tongling Bionic in its N-PORT filings yet. We sweep new filings monthly.